SCHEMBL610191

SCHEMBL610191

O=C(NC1CCC(O)CC1)[C@H]1CCCN(S(=O)(=O)c2cccc(F)c2)C1

nearest known ligand 0.72

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.72
KMT2A Q03164 5/20 0.65
TDP1 Q9NUW8 1/20 0.57
RAB9A P51151 2/20 0.57
NPC1 O15118 1/20 0.54
ATM Q13315 1/20 0.54
MEN1 O00255 1/20 0.53
TSHR P16473 2/20 0.53
PKM P14618 1/20 0.53
LMNA P02545 2/20 0.52
GAA P10253 2/20 0.52
MAPT P10636 2/20 0.52
HTT P42858 1/20 0.52
EPHX2 P34913 2/20 0.51
HSD11B1 P28845 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4960549 1.00 POLB (0.72) POLBKMT2ATDP1RAB9ANPC1
SCHEMBL610190 1.00 POLB (0.72) POLBKMT2ATDP1RAB9ANPC1
SCHEMBL4961351 0.89 POLB (0.68) POLBKMT2ATDP1RAB9AMEN1
SCHEMBL611833 0.89 POLB (0.68) POLBKMT2ATDP1RAB9AMEN1
SCHEMBL4961180 0.88 TDP1 (0.57) POLBKMT2ATDP1RAB9ANPC1
SCHEMBL611727 0.88 EPHX2 (0.67) POLBKMT2ATDP1RAB9ANPC1
SCHEMBL610400 0.88 TDP1 (0.57) POLBKMT2ATDP1RAB9ANPC1
SCHEMBL611728 0.88 EPHX2 (0.67) POLBKMT2ATDP1RAB9ANPC1
SCHEMBL4964663 0.88 RAB9A (0.62) POLBKMT2ATDP1RAB9ANPC1
SCHEMBL610399 0.88 TDP1 (0.57) POLBKMT2ATDP1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288417-B2 N-substituted piperidines and their use as pharmaceuticals INCYTE CORPORATION (US) 2012-10-16 US claimed
US-20120040964-A1 N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2012-02-16 US claimed
US-20060004049-A1 N-substituted piperidines and their use as pharrmaceuticals INCYTE CORPORATION 2006-01-05 US claimed
US-8288417-B2 N-substituted piperidines and their use as pharmaceuticals INCYTE CORPORATION (US) 2012-10-16 US disclosed
US-20120040964-A1 N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2012-02-16 US disclosed
US-8071624-B2 N-substituted piperidines and their use as pharmaceuticals INCYTE CORPORATION (US) 2011-12-06 US disclosed
EP-1758580-A4 N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2008-01-16 EP disclosed
EP-1758580-A2 N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-03-07 EP disclosed
WO-2006012226-A2 N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-02-02 WO disclosed
US-20060004049-A1 N-substituted piperidines and their use as pharrmaceuticals INCYTE CORPORATION 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040964-A1 N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS HSD11B1, CYP11B1, HSD3B1 POLB 1184/4885KMT2A 2726/4885TDP1 2819/4885
US-20060004049-A1 N-substituted piperidines and their use as pharrmaceuticals HSD11B1, HSD3B1, HSD11B2 POLB 1100/4885KMT2A 3003/4885TDP1 2527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.